Othman Al-Sawaf, MD University Hospital, Cologne 5Live #ASCO20
3:48
Key Insights on Fixed-duration venetoclax-obinutuzumab for previously untreated patients with chronic lymphocytic leukemia: Follow-up of efficacy and safety results from the multicenter, open-label, randomized, phase III CLL14 trial
Chronic Lymphocytic Leukemia
Othman Al-Sawaf, MD University Hospital, Cologne 5Live #ASCO20
Key Insights on Fixed-duration venetoclax-obinutuzumab for previously untreated patients with chronic lymphocytic leukemia: Follow-up of efficacy and safety results from the multicenter, open-label, randomized, phase III CLL14 trial
Chronic Lymphocytic Leukemia Similar Videos
Similar Videos
-
Recently presented data and optimal therapeutic approaches in relapsed/refractory CLL_Jennifer Brown, MD, PhD; #BeyondASCO
13:52
-
Susan O’Brien, MD; University of California Irvine; #DDHO2022
20:24
-
Module 3_Treatment Strategies in the Relapsed Refractory Setting_Matthew Davids, MD, MMSc_Jeffrey Bubis, DO, FACOI, FACP_Divis Khaira, MD
11:17
